Portland, OR -- (SBWIRE) -- 09/07/2017 -- The major factors that drive the growth of the Global Heparin Sodium Market are increase in the incidence of thrombosis, rise in government funding towards improving healthcare facilities, and rising awareness among the patient population regarding the availability of such treatment options. However, stringent government regulations and lack of awareness among the patient population regarding the availability of such treatment options restrict the market growth. However, unmet medical needs in emerging economies attract key players to invest on healthcare treatment modalities. This is anticipated to provide lucrative growth opportunities for the global heparin sodium market.

The global heparin sodium market is segmented on the basis of type and application. Based on type, the market is categorised into unfractionated heparin, low molecular weight heparins, and heparinoids. In terms of application, the market is divided into venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter, and others. Regionally, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of the market are Shenzhen Hepalink, Sichuan Deebio Pharmaceutical Co.LTD., Nanjing Xinbai Pharmaceutical Co., Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd, Yantai Dongcheng Biochemicals Co. Ltd., Pharma Action GmbH, Opocrin S.p.A, Bioibrica, Aspen Oss BV, and Pfizer Inc.

Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3477

Heparin Sodium Market Key Segments:

By Type

- Unfractionated Heparin
- Low Molecular Weight Heparins
- Heparinoids

By Application

- Venous Thromboembolism
- Complications of Pregnancy
- Cardioversion of Atrial Fibrillation/Flutter
- Others

Early buyers will receive 20% customization on this report